OACC · Oaktree Acquisition Corp. III Life Sciences
$10.65
+0.00 (+0.00%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Such potential liquidity shortfalls and mandatory liquidation condition raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$261.81M
Shares
24.58M
Volume · Oct 20
670
Avg daily vol (3M)
60.45K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.65
Open$10.65
Day$10.65–10.66
52W close$10.50–10.93
Avg vol 30d59K
Short int191 · 0.0% float · 1.0d
Short vol7%
DataDec 2024–Oct 2026
Filing10-Q · Aug 12
Up next
filed Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
$6.75M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
38.9
Trailing earnings · reciprocal yield 2.6%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.18M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+0.7%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very Low
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+0%
above
Price vs 50-day avg
−1%
below
RSI (14)
41
neutral
MACD trend
Negative
52-week position
35%
mid-range
Momentum
relative strength
1-month return
−1%
trailing
6-month return
+1%
trailing
YTD return
+1%
this year
Relative strength
−7%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $11 › 200d $11 — 50d above 200d
Institutional flow
Distributing
-2% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.00% of float · ▼ -8.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
57 holders — near 1-yr high, broad support
Squeeze score
33
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
6%
annualized · 1-yr
Max drawdown
−3%
past year
ATR
0.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+0%
Bullish
Price vs 50-day avg
−1%
Neutral
RSI (14)
41
Neutral
MACD trend
Negative
Bearish
52-week position
35%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $11 › 200d $11 — 50d above 200d
Institutional flow
Distributing
-2% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.00% of float · ▼ -8.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
57 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $11
Now $11 · 35%
Range high $11
vs 200-day avg +0%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Shell Companies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OACC
this stock
Oaktree Acquisition Corp. III Life Sciences
|
$261.81M | +0.7% | — | — | 0.0% |
|
VYLR
Vylor Inc.
|
$48.31B | — | — | — | — |
|
CLUS
Cluster Group Holdings Ltd Co
|
$8.00B | — | — | — | — |
|
DMII
Drugs Made In America Acquisition II Corp.
|
$648.15M | +2.8% | — | — | 0.2% |
|
EVAC
EQV Ventures Acquisition Corp. II
|
$603.18M | +2.9% | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
SEC Filings
Latest
8-K
- Filed
- Oct 16, 2026
- This year
- 9
Oaktree Acquisition Corp. III Life Sciences postponed its shareholder General Meeting, originally set for October 16, 2026, to October 23, 2026 at 10:00 a.m. Eastern Time to permit further proxy solicitation for the initial business combination extension proposal.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OACC | -0.9% | -1.4% | +0.7% | -1.2% | +0.7% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | +0.6% | -0.5% | -7.0% | -1.7% | -11.7% |